Cancer Research Targets  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on June 30, 2009
[Cancer Research, 10.1158/0008-5472.CAN-09-0145]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-09-0145v1
69/14/5961    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kadariya, Y.
Right arrow Articles by Kruger, W. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kadariya, Y.
Right arrow Articles by Kruger, W. D.

Molecular Biology, Pathobiology, and Genetics

Mice Heterozygous for Germ-line Mutations in Methylthioadenosine Phosphorylase (MTAP) Die Prematurely of T-Cell Lymphoma

Yuwaraj Kadariya 1, Bu Yin 4, Baiqing Tang 1, Susan A. Shinton 2, Eoin P. Quinlivan 5, Xiang Hua 2, Andres Klein-Szanto 3, Tahseen I. Al-Saleem 3, Craig H. Bassing 4, Richard R. Hardy 2, and Warren D. Kruger 1*

Divisions of 1Population Science, 2Basic Science, and 3Medical Science, Fox Chase Cancer Center; 4Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and 5Biomedical Mass Spectrometry Laboratory, General Clinical Research Center, University of Florida, Gainesville, Florida

* To whom correspondence should be addressed. E-mail: warren.kruger{at}fccc.edu.


   Abstract

Large homozygous deletions of 9p21 that inactivate CDKN2A, ARF, and MTAP are common in a wide variety of human cancers. The role for CDKN2A and ARF in tumorigenesis is well established, but whether MTAP loss directly affects tumorigenesis is unclear. MTAP encodes the enzyme methylthioadenosine phosphorylase, a key enzyme in the methionine salvage pathway. To determine if loss of MTAP plays a functional role in tumorigenesis, we have created an MTAP-knockout mouse. Mice homozygous for a MTAP null allele (MtaplacZ) have an embryonic lethal phenotype dying around day 8 postconception. Mtap/MtaplacZ heterozygotes are born at Mendelian frequencies and appear indistinguishable from wild-type mice during the first year of life, but they tend to die prematurely with a median survival of 585 days. Autopsies on these animals reveal that they have greatly enlarged spleens, altered thymic histology, and lymphocytic infiltration of their livers, consistent with lymphoma. Immunohistochemical staining and fluorescence-activated cell sorting analysis indicate that these lymphomas are primarily T-cell in origin. Lymphoma-infiltrated tissues tend to have reduced levels of Mtap mRNA and MTAP protein in addition to unaltered levels of methyldeoxycytidine. These studies show that Mtap is a tumor suppressor gene independent of CDKN2A and ARF. [Cancer Res 2009;69(14):5961–9]

Key Words: Cancer, Tumor Suppressor Gene, Methionine, Embryonic Lethal







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.